Indication
Details coming soon
Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Symptomatic anaemia of chronic kidney disease Age: Adult Condition: Patients not currently treated with an erythropoiesis-stimulating agent (ESA), stage 3 to 5 chronic kidney disease with no iron deficiency and not on dialysis |
Dose: Oral – 70 mg Frequency: three times per week Note: Not on consecutive days. Ensure adequate iron stores prior to initiation. Achieve and maintain target Haemoglobin levels of 10 to 12 g/dL. Dose can be adjusted stepwise up or down 4 weeks after treatment start, and every 4 weeks thereafter. If Haemoglobin increases by more than 2 g/dL, reduce dose by one step immediately. Maximum dose: 3 mg/kg body weight or 300 mg three times per week, whichever is lower. Treatment should not be continued beyond 24 weeks if clinically meaningful increase in Haemoglobin is not achieved. |
|
Indication: Symptomatic anaemia of chronic kidney disease Age: Adult Condition: Patients not currently treated with an erythropoiesis-stimulating agent (ESA), stage 3 to 5 chronic kidney disease with no iron deficiency and not on dialysis |
Dose: Oral – 100 mg Frequency: three times per week Note: Not on consecutive days. Ensure adequate iron stores prior to initiation. Achieve and maintain target Haemoglobin levels of 10 to 12 g/dL. Dose can be adjusted stepwise up or down 4 weeks after treatment start, and every 4 weeks thereafter. If Haemoglobin increases by more than 2 g/dL, reduce dose by one step immediately. Maximum dose: 3 mg/kg body weight or 300 mg three times per week, whichever is lower. Treatment should not be continued beyond 24 weeks if clinically meaningful increase in Haemoglobin is not achieved. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Not applicable – Not applicable Note: No approved pediatric dosage available |
Administration
- May be taken orally with or without food
- Take at regular intervals
Side Effect
- hypertension (13.9%)
- vascular access thrombosis (12.8%)
- diarrhoea (11.8%)
- peripheral oedema (11.7%)
- hyperkalaemia (10.9%) and nausea (10.2%)
- sepsis (3.4%)
- hyperkalaemia (2.5%)
- hypertension (1.4%) and Deep vein thrombosis (DVT) (1.2%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Phosphate binders (sevelamer carbonate, calcium acetate)
|
Decreased roxadustat AUC and Cmax
|
|
Multivalent cations (calcium, iron, magnesium, aluminum)
|
May form chelates; stagger administration by at least 1 hour
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.